US0070021086 - Common Stock
ADICET BIO INC
NASDAQ:ACET (4/25/2024, 3:30:00 PM)
After market: 1.86 +0.05 (+2.76%)1.81
-0.06 (-3.47%)
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. The company is headquartered in Boston, Massachusetts and currently employs 132 full-time employees. The company went IPO on 2018-01-26. The firm is engaged in discovering and developing allogeneic gamma delta T cell therapies for cancer. The firm is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. Its product candidate, ADI-001, is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20 used for the treatment of relapsed or refractory B-cell non-Hodgkins lymphoma (NHL). Its pipeline also includes ADI-925, which is a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Its pipeline also includes additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
ADICET BIO INC
200 Berkeley Street, 19th Floor
Boston MASSACHUSETTS 02116
P: 16174822333
CEO: Chen Schor
Employees: 132
Website: https://www.adicetbio.com/
Although speculation can be bad for your blood pressure, these compelling penny stocks have some strong endorsements.
ACET stock results show that Adicet Bio met analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adicet Bio (NASDAQ:ACET) just reported results for the fourth quarter of 2023.A...
Here you can normally see the latest stock twits on ACET, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: